DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Jevtana (Cabazitaxel) - Published Studies

 
 



Jevtana Related Published Studies

Well-designed clinical trials related to Jevtana (Cabazitaxel)

TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. [2011.04]

Other research related to Jevtana (Cabazitaxel)

Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. [2013]

Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer. [2012]

The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. [2012]

Cabazitaxel: a novel microtubule inhibitor. [2011.07.09]

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. [2011.05]

Cabazitaxel for the treatment of prostate cancer. [2011.04]

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. [2011.03.10]

Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. [2011.01.12]

Cabazitaxel for the treatment of castration-resistant prostate cancer. [2011.01]

Critical appraisal of cabazitaxel in the management of advanced prostate cancer. [2010.12.03]

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. [2010.10.02]

Cabazitaxel, a new taxane with favorable properties. [2010.10]

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. [2010]

Other possibly related research studies

[New drugs at the horizon for men with prostate cancer] [2010.05.26]

Castration-resistant prostate cancer: current and emerging treatment strategies. [2010.05.28]

Overcoming chemotherapy resistance in prostate cancer. [2011.06.15]

New options for the management of castration-resistant prostate cancer: a case perspective. [2011.02]

Current clinical trials in castrate-resistant prostate cancer. [2011.06]

Contemporary management of metastatic castration-resistant prostate cancer. [2011.05]

[Castration resistant prostate cancer 2011]. [2011.03]

Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. [2011.03]

Optimal management of bone metastases in prostate cancer. [2011.06]

A renaissance in the medical treatment of advanced prostate cancer. [2010.12]

Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. [2010.12.01]

Horizon scanning for novel therapeutics for the treatment of prostate cancer. [2010.12]

New and emerging agents for the treatment of castration-resistant prostate cancer. [2011.11]

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. [2011.11.12]

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? [2011]

Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). [2011.10.28]

New treatment options for patients with metastatic castration-resistant prostate cancer. [2011.09.22]

Second-line therapy for castrate-resistant prostate cancer: a literature review. [2011.09]

Chemotherapy-based treatment for castration-resistant prostate cancer. [2011.09.20]

Evolving therapeutic paradigms for advanced prostate cancer. [2011.05]

Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. [2011.06.15]

Updates on therapeutic targets and agents in castration-resistant prostate cancer. [2011.06]

Broadening horizons in medical management of prostate cancer. [2011.06]

Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. [2011.09]

New therapies for castration-resistant prostate cancer: efficacy and safety. [2011.08]

Pathways of chemotherapy resistance in castration-resistant prostate cancer. [2011.07.04]

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. [2011.04.23]

Current treatment strategies for castration-resistant prostate cancer. [2011.03]

Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. [2011.04]

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. [2011.04]

Novel agents and new therapeutics in castration-resistant prostate cancer. [2011.05]

[Actualities in prostate cancer in ASCO annual meeting 2010]. [2010.12]

Management of metastatic castration-resistant prostate cancer: recent advances. [2012]

Chemotherapy-based treatment for castration-resistant prostate cancer. [2011]

Pharmacotherapeutic management of locally advanced prostate cancer: current status. [2011]

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. [2011]

Current clinical trials in castrate-resistant prostate cancer. [2011]

Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. [2014]

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. [2013]

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. [2014]

The changing landscape in metastatic castration-resistant prostate cancer. [2013]

Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? [2013]

Metabolic and toxicological considerations of newly approved prostate cancer drugs. [2013]

New agents in the arsenal to fight castrate-resistant prostate cancer. [2013]

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. [2014]

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. [2014]

Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017